Name | Bemnifosbuvir hemisulfate |
Description | Bemnifosbuvir hemisulfate (AT-527) is a potent inhibitor of HCV virus replication. |
In vitro | The potent in vitro activity of AT-511, the free base of bemnifosbuvir hemisulfate, against several coronaviruses, including SARS-CoV-2. In normal human airway epithelial cells, the concentration of AT-511 required to inhibit replication of SARS-CoV-2 by 90% (EC90) was 0.47?μM, very similar to its EC90 against human coronavirus (HCoV)-229E, HCoV-OC43, and SARS-CoV in Huh-7 cells[1]. |
In vivo | When given orally to rats and monkeys, bemnifosbuvir hemisulfate preferentially delivered high levels of AT-9010 in the liver in vivo.These favorable preclinical attributes support bemnifosbuvir hemisulfate may increase SVR rates[2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 170 mg/mL (269.60 mM), Sonication is recommended.
|
Keywords | Inhibitor | antiviral | phosphoramidate | HCV | nucleotide | Bemnifosbuvir | SARS-CoV | pangenotypic | Bemnifosbuvir hemisulfate | AT 527 | Bemnifosbuvir Hemisulfate | guanosine | SARS coronavirus | AT527 | Hepatitis C virus | inhibit |
Inhibitors Related | Nirmatrelvir | EIDD-1931 | Remdesivir | Ribavirin | Silymarin | Umifenovir hydrochloride | Sofosbuvir | Hydroxychloroquine | Ritonavir | Chloroquine phosphate | Artemisinin | Favipiravir |
Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Infection Compound Library | Nucleotide Compound Library |